Leukocyte-platelet aggregates and monocyte tissue factor expression in bovines implanted with ventricular assist devices.

Infection and thromboembolism remain significant complications associated with ventricular assist device (VAD) support, including the newer rotary VADs, limiting wider adoption of this promising technology. These complications persist in spite of extensive preclinical testing in large animal models. The amount of biocompatibility information collected during preclinical trials is limited due to a lack of available assays. We thus developed three flow cytometric assays to measure leukocyte-platelet aggregates and monocyte tissue factor expression and applied them to 26 bovines implanted with two types of rotary VADs. All animals displayed low levels of circulating aggregates and monocytes expressing tissue factor prior to device implant. The assay values significantly increased following VAD implant, then usually declined to a lower, yet significantly elevated versus baseline, level indicative of ongoing inflammation. The implementation of more robust biocompatibility assays for the evaluation of cardiovascular device performance and modification might ultimately contribute to the development of safer artificial organs.

[1]  Silviu Itescu,et al.  Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist de vice , 1999, The Lancet.

[2]  Matthias Loebe,et al.  What Price Support? Ventricular Assist Device Induced Systemic Response , 2003, ASAIO journal.

[3]  J. Arnout,et al.  Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. , 2002, The Journal of thoracic and cardiovascular surgery.

[4]  R. Bach,et al.  Monoclonal antibodies against bovine tissue factor, which block interaction with factor VIIa. , 1985, Blood.

[5]  E. Verrier,et al.  Systemic consequences of ventricular assist devices: alterations of coagulation, immune function, inflammation, and the neuroendocrine system. , 2002, Artificial organs.

[6]  M. Furman,et al.  Circulating Monocyte-Platelet Aggregates Are a More Sensitive Marker of In Vivo Platelet Activation Than Platelet Surface P-Selectin: Studies in Baboons, Human Coronary Intervention, and Human Acute Myocardial Infarction , 2001, Circulation.

[7]  D. Loisance,et al.  Platelet activation and aggregation profile in prolonged external ventricular support. , 2004, The Journal of thoracic and cardiovascular surgery.

[8]  M. Doré.  Platelet-leukocyte interactions. , 1998, American heart journal.

[9]  J. Loscalzo,et al.  Platelet-monocyte aggregates: bridging thrombosis and inflammation. , 2002, Circulation.

[10]  F. Veglia,et al.  Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery. , 2005, The Journal of thoracic and cardiovascular surgery.

[11]  V. Videm,et al.  Heart surgery with extracorporeal circulation leads to platelet activation at the time of hospital discharge. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[12]  F. Neumann,et al.  Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. , 1997, Circulation.

[13]  H. Lewin,et al.  The development and analysis of species specific and cross reactive monoclonal antibodies to leukocyte differentiation antigens and antigens of the major histocompatibility complex for use in the study of the immune system in cattle and other species. , 1987, Veterinary immunology and immunopathology.

[14]  S. Wisniewski,et al.  Measurement of hemostatic indexes in conjunction with transcranial doppler sonography in patients with ventricular assist devices. , 1999, Stroke.

[15]  B. Reichart,et al.  Platelet activation markers in patients with heart assist device. , 2005, Artificial organs.

[16]  James W Long,et al.  Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. , 2005, Congestive heart failure.

[17]  W. Wagner,et al.  Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients. , 1998, The Annals of thoracic surgery.

[18]  J. Vaage,et al.  Hemostasis in off-pump compared to on-pump coronary artery bypass grafting: a prospective, randomized study. , 2005, The Annals of thoracic surgery.

[19]  M. Amrani,et al.  Off-pump coronary artery bypass surgery is associated with reduced neutrophil activation as measured by the expression of CD11b: a prospective randomized study. , 2005, The heart surgery forum.

[20]  K. Litwak,et al.  Platelet activation, aggregation, and life span in calves implanted with axial flow ventricular assist devices. , 2002, The Annals of thoracic surgery.

[21]  L. Jonasson,et al.  Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. , 2005, The American journal of cardiology.

[22]  N. Key,et al.  Elevated Whole-Blood Tissue Factor Procoagulant Activity as a Marker of Restenosis After Percutaneous Transluminal Coronary Angioplasty and Stent Implantation , 2003, Circulation.

[23]  J F Antaki,et al.  An implantable centrifugal blood pump with a recirculating purge system (Cool-Seal system). , 1998, Artificial organs.

[24]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[25]  W. Wagner,et al.  Flow cytometric assays to detect platelet activation and aggregation in device-implanted calves. , 1998, Journal of biomedical materials research.

[26]  B. Horne,et al.  Effect of mechanical circulatory support on outcomes after heart transplantation. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  R. Hetzer,et al.  Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. , 2001, European heart journal.

[28]  P. Gentry,et al.  Neutrophil-platelet interactions and their relevance to bovine respiratory disease. , 2001, Veterinary journal.

[29]  G. Torre-Amione.  Immune activation in chronic heart failure. , 2005, The American journal of cardiology.

[30]  B. Griffith,et al.  Chronic animal health assessment during axial ventricular assistance: importance of hemorheologic parameters. , 1999, ASAIO journal.

[31]  R. Goldberg,et al.  Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. , 2001, Journal of the American College of Cardiology.

[32]  P. Hjemdahl,et al.  Platelet-Leukocyte Cross Talk in Whole Blood , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[33]  R. Peters,et al.  Tissue factor and coronary artery disease. , 2002, Cardiovascular research.

[34]  James H Morrissey,et al.  Tissue factor as a proinflammatory agent , 2002, Arthritis Research & Therapy.

[35]  M. Ray,et al.  Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab. , 2005, International journal of cardiology.

[36]  P. Sopp,et al.  Cross-reactivity of monoclonal antibodies to defined human leucocyte differentiation antigens with bovine cells. , 1997, Veterinary immunology and immunopathology.

[37]  Mitsuo Umezu,et al.  In vivo evaluation of a MPC polymer coated continuous flow left ventricular assist system. , 2003, Artificial organs.

[38]  K M Taylor,et al.  The platelet in cardiopulmonary bypass. , 1998, The Annals of thoracic surgery.

[39]  F. Veglia,et al.  The role of tissue factor and P-selectin in the procoagulant response that occurs in the first month after on-pump and off-pump coronary artery bypass grafting. , 2005, The Journal of thoracic and cardiovascular surgery.